Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Approaches to Contact Dermatitis in the Atopic Dermatitis Patient
Description
Dr. Alex Flam, an associate professor of dermatology, discusses the complexities of managing contact dermatitis in patients with atopic dermatitis (AD). The presentation highlights challenges in diagnosing and differentiating between allergic contact dermatitis (ACD) and atopic dermatitis, emphasizing that both conditions often overlap. Dr. Flam notes that patients with AD may have an increased incidence of ACD due to skin barrier abnormalities, altered bacterial colonization, and increased exposure to allergens. Key allergens in AD patients include metals, fragrances, and preservatives, specifically formaldehyde and its releasers. The impact of newer medications, such as dupilumab and JAK inhibitors, on patch testing results is also discussed, indicating that they may affect reactivity and testing outcomes. Despite challenges, patch testing remains essential for accurately diagnosing ACD in AD patients, particularly when symptoms persist despite treatment. Dr. Flam concludes that a comprehensive approach, including considering patch testing during treatment with biologics, can help effectively manage recalcitrant cases.
View moreConclusions
- There is a significant overlap in clinical findings between atopic dermatitis (AD) and allergic contact dermatitis (ACD).
- Dermatologists must utilize patch testing as a critical tool to differentiate between AD and ACD due to the challenges in diagnosis based on clinical presentation alone.
- Patients with atopic dermatitis are at greater risk for developing allergic contact dermatitis and may have higher rates of sensitization to specific allergens such as metals, fragrances, and preservatives.
- Skin barrier abnormalities in atopic dermatitis can facilitate increased penetration of haptens leading to allergic contact dermatitis.
- Altered bacterial colonization, particularly staphylococcus aureus, in atopic dermatitis may influence the development of allergic contact dermatitis by affecting sensitization.
- Filaggrin mutations associated with atopic dermatitis can correlate with increased sensitization to allergens like nickel.
- Prolonged exposure to topical treatments in patients with atopic dermatitis may contribute to an increased risk of sensitization and development of allergic contact dermatitis.
- The introduction of newer medications for treating atopic dermatitis, like dupilumab, may influence patch testing results and the clinical management of allergic contact dermatitis in these patients.
- Czarnobilska et al, 2014: 20% of children and 52% of adolescents with flexural eczema were diagnosed with ACD while having insufficient features for AD
- Niels K. Veien Thais Hattel, Grete Laurberg. Contact dermatitis: First published: 23 May 2008 | https://doi.org/10.1111/j.1600-0536.2008.01345.x
- Henry E. Jones, MC; Charles W. Lewis, MC; Stacey L. McMarlin, MC. Allergic Contact Sensitivity in Atopic Dermatitis. Arch Dermatol. 1973;107(2):217-222. doi:10.1001/archderm.1973.01620170029009
- Malajian D & Belsito D. Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis. Dermatology
- Hereford et al. Dermatitis, 2021
- Biedermann et al. TH1 and TH2 Lymphocyte Development and Regulation of TH Cell-Mediated Immune Responses of the Skin.
- Kim BE & Leung DYM. Allergy Asthma Immunol Res. 2018
- A. Borok, J. D. Johansen, M. Deleuran, C. G. Mortz; Children with atopic dermatitis may have unacknowledged contact allergies contributing to their skin symptoms. A.B. Simonsen,1,2 ·* J.D. Johansen,2 M. Deleuran,1 C.G. Mortz,4 L. Skov,3 M. Sommerlund1
- Mailhol C et al. Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children.
- Sandler et al, JAAD, 2025
- Chovatiya R & Paller A. Journal of Allergy and Clinical Immunology, 2021.
- Laurence Mainville Hélène Veillette, Marie-Claude Houle. Sequential patch testing in a patient treated with dupilumab then with upadacitinib: Differences in patch test results as well as in disease control. SAGE Open Med Case Rep. 2024 Dec 15;12:2050313X241304949. doi: 10.1177/2050313X241304949
- Miguel Antonio Lasheras-Pérez, Javier Miquel-Miquel et al. Negative patch test findings after initiation of upadacitinib: A case report. First published: 30 December 2024 | https://doi-org.ezproxy.med.nyu.edu/10.1111/cod.14751